{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Response rate (Percentage of participants achieving CR + PR among all the enrolled and treated patients) as defined by modified International Working Group (IWG) criteria (2006) in the LIC. CR was defined as having responses of hemoglobin ≥11 g/dL, neutrophils ≥1 x 10\\^9/L, platelets ≥1 x 10\\^11/L, percentage of blasts = 0%, percentage of BMB≤5%, and normal maturation of all cell lines (note if has persistent dysplasia), and all responses must last at least 4 weeks. PR was defined as meeting all CR criteria if abnormal before treatment except BMB, percentage of BMB decreased by ≥50% but still \\>5% for at least 4 weeks.","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"}],"paramType":"NUMBER","populationDescription":"The safety analysis population included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of approximately 16 months","title":"Percentage of Participants Achieving Complete Remission (CR) + Partial Remission (PR) in the LIC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}